Does Pulmonary Rehabilitation improve the health of people in Kyrgyzstan living with lung disease caused by tuberculosis?
- Conditions
- RespiratoryPost-TB lung disease
- Registration Number
- ISRCTN11122503
- Lead Sponsor
- niversity of Leicester
- Brief Summary
2022 Interim results article in https://pubmed.ncbi.nlm.nih.gov/35121602/ Qualitative results (added 07/02/2022) 2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35190411/ (added 23/02/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 114
Stage 1 (patient):
1. Aged =18 years
2. Physician diagnosis of COPD
Stage 1 (staff):
1. Healthcare staff that would typically refer patients to a clinical PR programme, such as physicians & clinicians.
Stage 2:
1. Aged =18 years;
2. Definite diagnosis of a TB-negative patients with PTBLD lung disease
3. Previous TB treatment or finished treatment
4. Medical Research Council dyspnoea score grade 2 or higher
Stage 1 (patients):
1. Unable or unwilling to provide informed consent
Stage 2 (staff):
1. Unable or unwilling to provide informed consent
Stage 2:
1. Comorbidities such as severe or unstable cardiovascular, other internal diseases and locomotor difficulties that preclude exercise
2. Malignant disease such as lung cancer
3. Evidence of active TB on Chest X-ray or sputum tests within 1 month of assessment
4. Unable or unwilling to provide informed consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Walking distance (exercise capacity) on the Incremental Shuttle Walk Test (ISWT) at baseline and 6 weeks
- Secondary Outcome Measures
Name Time Method